PATENT CLAIM ANALYSIS

Application Number: 16385062
Application Type: Utility
Filing Date: 2019-04
Publication Date: 2019-08
Patent Classification: ["424", "207100"]

Abstract:
Methods for inducing an immune response against Human Immunodeficiency Virus (HIV) in HIV-infected subjects undergoing antiretroviral therapy (ART) are described. The methods include administering an adenovirus vector primer vaccine and a modified vaccinia virus (MVA) vector booster vaccine encoding mosaic HIV antigens.

Claim (Index 15):
The method according to  claim 12 , wherein the primer vaccine is re-administered at about 12 weeks after the primer vaccine is initially administered, the booster vaccine is first administered at about 24 weeks after the primer vaccine is initially administered, and the booster vaccine is re-administered at about 48 weeks after the primer vaccine is initially administered.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 100.0
- Lexical Diversity: 1.21951
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15693650', '15968834', '14863808', '15380123', '14632433']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7194469774214538
- 35 USC 102 Novelty (BERT): 0.6868944630480421
- Combined Prediction Score: 0.7161917259841126
- Mean Citation Score: 488.40392
- Max Citation Score: 690.0668
- Similarity Product: 674.5781113676071

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test